Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

NCT03916627 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Hepatocellular Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: cemiplimab
DRUG: Platinum Doublet
DRUG: fianlimab

Sponsor

Regeneron Pharmaceuticals